Related references
Note: Only part of the references are listed.Monitoring CD27+memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study
M. Cohen et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2017)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Efficacy of rituximab in refractory neuromyelitis optica
N. Collongues et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Rapid exacerbation of neuromyelitis optica after rituximab treatment
Yongqiang Dai et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2016)
Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders A Systematic Review and Meta-analysis
Valentina Damato et al.
JAMA NEUROLOGY (2016)
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Dean M. Wingerchuk et al.
NEUROLOGY (2015)
Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica Influence of FCGR3A Polymorphisms on the Therapeutic Response to Rituximab
Su-Hyun Kim et al.
JAMA NEUROLOGY (2015)
Repeated Treatment With Rituximab Based on the Assessment of Peripheral Circulating Memory B Cells in Patients With Relapsing Neuromyelitis Optica Over 2 Years
Su-Hyun Kim et al.
ARCHIVES OF NEUROLOGY (2011)
Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels
Ichiro Nakashima et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2011)
Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab
H. L. Pellkofer et al.
NEUROLOGY (2011)
Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice
Samira Saadoun et al.
BRAIN (2010)
Neuromyelitis Optica: Pathogenicity of Patient Immunoglobulin In Vivo
Monika Bradl et al.
ANNALS OF NEUROLOGY (2009)
Intrathecal Pathogenic Anti-Aquaporin-4 Antibodies in Early Neuromyelitis Optica
Jeffrey L. Bennett et al.
ANNALS OF NEUROLOGY (2009)
Treatment of Neuromyelitis Optica With Mycophenolate Mofetil
Anu Jacob et al.
ARCHIVES OF NEUROLOGY (2009)
Neuromyelitis optica: Passive transfer to rats by human immunoglobulin
Makoto Kinoshita et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Monoclonal antibodies and progressive multifocal leukoencephalopathy
Joseph R. Berger et al.
MABS (2009)
Treatment of Neuromyelitis Optica With Rituximab Retrospective Analysis of 25 Patients
Anu Jacob et al.
ARCHIVES OF NEUROLOGY (2008)
Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
S. Jarius et al.
BRAIN (2008)
Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica
B. Weinstock-Guttman et al.
MULTIPLE SCLEROSIS JOURNAL (2008)
NMO-IgG predicts the outcome of recurrent optic neuritis
M. Matiello et al.
NEUROLOGY (2008)
B cells move to centre stage: novel opportunities for autoimmune disease treatment
Jeffrey L. Browning
NATURE REVIEWS DRUG DISCOVERY (2006)
Revised diagnostic criteria for neuromyelitis optica
D. M. Wingerchuk et al.
NEUROLOGY (2006)
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis
BG Weinshenker et al.
ANNALS OF NEUROLOGY (2006)
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
VA Lennon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
An open label study of the effects of rituximab in neuromyelitis optica
BAC Cree et al.
NEUROLOGY (2005)
Prospects for B-cell-targeted therapy in autoimmune disease
JCW Edwards et al.
RHEUMATOLOGY (2005)